Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selgantolimod + tenofovir alafenamide
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Selgantolimod + tenofovir alafenamide is an investigational oral combination therapy for chronic hepatitis B virus (HBV) infection. **Selgantolimod** is a small molecule agonist of **Toll-like receptor 8 (TLR8)**, acting as an immunomodulator to stimulate immune responses, including increased cytokine and chemokine production and redistribution of immune cell subsets. **Tenofovir alafenamide** is a nucleotide reverse transcriptase inhibitor (NRTI), a prodrug of tenofovir, that is phosphorylated intracellularly to its active form, tenofovir diphosphate, which inhibits HBV replication by incorporation into viral DNA and chain termination. The combination aims for additive or synergistic effects targeting both viral replication (by TAF) and host immune activation (by selgantolimod) for potentially achieving functional HBV cure. This combination has shown modest declines in HBsAg and good safety/tolerability in phase II trials.[1][3]
- Other names
- TAF + selgantolimod
02
Targets
TLR8 (Toll-like receptor 8)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on selgantolimod + tenofovir alafenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selgantolimod + tenofovir alafenamide.